Choose a language and wait for the translated text.
Shots:
Savara has been informed by the US FDA that it will not meet the PDUFA target action date of Nov 22, 2026, for the BLA of molgramostim inhalation solution to treat autoimmune pulmonary alveolar proteinosis (autoimmune PAP)
The BLA review is ongoing & the agency has not provided a revised action date; Savara stated it looks forward to working closely with the FDA to complete the review
Autoimmune PAP is a rare lung disease in which autoantibodies neutralize GM-CSF, leaving alveolar macrophages unable to clear surfactant, which builds up in the alveoli and impairs gas transfer
Ref: Business Wire | Image: Savara | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Savara Reports the US FDA Will Not Act on Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis by the PDUFA Date appeared first on PharmaShots.
Savara Reports the US FDA Will Not Act on Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis by the PDUFA Date | PharmaVoice